GeoVax Labs (GOVX)
Clinical developer of an mpox/smallpox vaccine and gene-directed therapy for head-and-neck cancer.
Something off on this page? Send us feedback.
Develops an unapproved mpox and smallpox vaccine candidate and a gene-therapy candidate for head-and-neck cancer, relying on external clinical and manufacturing partners, licensed technologies, and equity-linked financing rather than product sales.
Develops GEO-MVA, an MVA vaccine candidate for mpox and smallpox, and Gedeptin, a gene-directed enzyme/prodrug therapy for head-and-neck cancer. Neither program is approved or commercial, and no product-sale revenue has been generated.
Operates as a biotechnology research-and-development organization with a small internal workforce, using CROs, CMOs, licensors, and testing vendors to execute clinical development and manufacture supplies. GEO-MVA uses the MVA platform, while Gedeptin uses a separate adenoviral-vector platform.
Seeks to commercialize approved candidates internally or through licensing, partnerships, and government or international procurement. Progress depends on further clinical work, regulatory authorization, manufacturing scale-up, licensed intellectual property, third-party execution, and equity-linked financing.
Company facts
Target rangeAs of Sep 22, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Feb 19, 2026 | D. Boral Capital | Downgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $3.1M · Total debt $323.1K · Total assets $4.6M · Shareholders' equity $1.8M
- Revenue
- $0
- Operating income
- −$4.4M
- Net income
- −$4.4M
No dividends on record.
| Institutions | 6.69% | 493.2K shares | |
|---|---|---|---|
| 17 holders · as of Jun 30, 2026 | |||
| Insiders | 0.04% | 2.9K shares | |
| 5 holders · as of Aug 8, 2025 | |||
| Other | 93.27% | 6.87M shares | |
| remainder | |||
7.37M company shares as of Sep 23, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Jane Street Group, LLCInstitution | 4.28% | 315,275 | as of Jun 30, 2026 |
HRT Financial LPInstitution | 1.72% | 126,704 | as of Jun 30, 2026 |
Geode Capital Management, LLCInstitution | 0.29% | 21,112 | as of Jun 30, 2026 |
Two Sigma Securities, LLCInstitution | 0.14% | 10,682 | as of Jun 30, 2026 |
Vanguard Fiduciary Trust CoInstitution | 0.07% | 5,068 | as of Jun 30, 2026 |
Insider tradesForm 4
No open-market trades in the last 12 months.
- Emergent BioSolutions
ACAM2000 is an approved live vaccine for mpox/smallpox preparedness.
- Merck
KEYTRUDA sets the approved perioperative standard in resectable HNSCC.
- CEL-SCI
Multikine targets the same first-line neoadjuvant HNSCC setting.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| GeoVax Labs | $0.3601 | −0.88% | $2.7M | — | — | — | — |
| Emergent BioSolutions | $6.61 | −2.22% | $348.8M | — | — | 0.5 | +66.3% |
| Merck | $147.09 | −2.54% | $372.73B | 120.7 | 17.0 | 5.6 | +5.1% |
| CEL-SCI | $1.75 | +2.94% | $11.7M | — | — | — | — |
| Median | 120.7 | 17.0 | 3.0 | +35.7% |